MicroRNA-34 (miR-34) is one of the major families of tumor suppressor miRNAs often lost in cancers. Delivery of miR-34a mimics to affected tumors as a therapeutic strategy has been tried in pre-clinical studies and in a phase I clinical trial. One approach to increase efficacy and reduce toxicity is to rationally identify drug combinations with small molecules that synergize with miR-34a. In this study we performed a high-throughput screen of a large panel of small molecules with known biological activity and identified ouabain as a candidate small molecule that synergized with miR-34a in killing lung cancer cells. We elucidated autophagy activation as a key mechanism by which miR-34a and ouabain causes increased cytotoxicity in cells. We posit that this combinatorial approach could reduce the active dose of miR-34a needed in vivo to observe tumor shrinkage and potentiate the development of miR-34a combination therapies in the future.
HIGHLIGHTS miR-34a is a tumor suppressor miRNA downregulated in many cancers including lung cancer Screen identifying small molecule-miR-34a combinations against cancer cells established Small molecule ouabain acts in synergy with miR-34a to kill cancer cells Autophagy signaling was observed upon treatment of cancer cells with ouabain and miR-34
INTRODUCTION
Lung cancer has the number one mortality among all cancer types with an estimated number of deaths of 140,000 in year 2019 in the United States (Siegel et al., 2019) . The majority of patients are diagnosed with non-small cell lung cancer (NSCLC) and have aggressive metastasis and resistance to existing therapeutics. Novel therapeutic strategies based on rational drug combinations to overcome drug resistance is currently needed in the clinic. Of the family of noncoding RNAs (ncRNAs), microRNAs (miRNAs) exist as small ncRNAs and mediate target translational inhibition or degradation by binding to complementary regions in target mRNAs (Peng and Croce, 2016; Rupaimoole and Slack, 2017) . Since the discovery of the first miRNA in 1993 and 7 years later the first mammalian miRNA, let-7, currently more than 2,000 human miRNAs have been discovered (Bartel, 2004; Reinhart et al., 2000) . These miRNAs have been shown to regulate key cell signaling events such as apoptosis, proliferation, migration, and differentiation. Considering the widespread roles of miRNAs in cell biology, it is not surprising that a significant number of these miRNAs play roles in cancer progression (Bartel, 2004; Rupaimoole and Slack, 2017) . One such miRNA, miR-34a, is often downregulated in cancers and involved in oncogenic programming of cancer cells (Chang et al., 2007; Li et al., 2013; Liu et al., 2011) . Transcription of miR-34a is regulated by p53 binding to the promoter region of miR-34a and activating its transcription (Chang et al., 2007) . Major cancers such as lung and pancreatic cancers have shown to exhibit downregulation of miR-34a (Rupaimoole and Slack, 2017) . miR-34a has been shown to play roles in DNA damage response-mediated apoptosis by direct targeting of Sirtuin 1 (Li et al., 2013) . Numerous studies have shown a role for miR-34a as a tumor suppressor miRNA via targeting several cell cycle proteins such as CDK4/6, anti-apoptosis proteins such as BCL2, and metastasis-related proteins such as MYC and CD44 (Misso et al., 2014) .
In recent years, several preclinical studies have shown the potential for tumor suppressor miRNA replenishment as a viable therapeutic against cancers. Along this line, miR-34a replenishment therapy is one of the most widely tested miRNA strategies and has advanced to a phase I clinical trial against several solid and hematological malignancies (Bader, 2012) . In models of NSCLC, a liposomal formulation of miR-34a mimic was delivered to xenografted lung tumors and significant inhibition of tumor growth was observed (Trang et al., 2011) . Furthermore, tumors expressed lower levels of proteins that are regulated by miR-34a, such as MET and BCL2. In the Kras LSLÀG12D/+ ;Trp53 LSLÀR172H/+ model of NSCLC, which is highly resistant to anticancer therapies, viral vector-based and nanoparticle strategies to deliver inducible miR-34a also showed promise by decreasing tumor burden and targeting Bcl2 protein reduction (Kasinski and Slack, 2012; Kasinski et al., 2015) . Recently, miR-34a encapsulated in an early-generation lipid nanoparticle was tested in a clinical trial, and unfortunately, during the dose escalation stage, a small number of patients Compared with SALE, all cancer cell lines showed a significant reduction in miR-34a levels (p < 0.001), and compared with AALE, except for H650 and H358, all the cancer cell lines showed a significant reduction in miR-34a levels (p < 0.001). (B) miR-Control and miR-34a dose-response curves in non-small cell lung cancer cell lines (n = 10). Cells were transfected with miR-Control or miR-34a for 72 h, and viability was measured using the MTT reagent.
showed immune-related cytotoxicity and the trial ended (Beg et al., 2015) . The cause of the toxicity is unknown, but this issue reiterates the need for careful consideration of dosing and targeted therapeutics using nanoparticles with ligands to cancer cell receptors, avoiding off-target cytotoxicity or adversarial immune reactions.
In this current study we take a novel approach in an attempt to increase miR-34a therapeutic efficiency by identifying a possible combination therapy with small molecules. Using a high-throughput screen consisting of $10,000 small molecules of known biological activity, we identify ouabain as a top small molecule candidate to combine synergistically with miR-34a in killing lung cancer cells. We believe that the combination approach will help in reducing the effective dose for miR-34a needed in the clinic and could allow for a reduction in adverse reactions.
RESULTS AND DISCUSSION

A Screen of Lung Cancer Cells for miR-34a Sensitivity
Previous studies have shown that miR-34a induces apoptosis and reduces tumor growth in many cancer cell types, and lung cancer is one of the major cancer types among them. First, we measured miR-34a expression in a panel of lung cancer cell lines (n = 11) and compared this with immortalized lung epithelial cells SALE and AALE. We observed that, compared with AALE and SALE cells, many NSCLC cells have low expression of miR-34a, with A549 being one of the least expressing cells ( Figure 1A ). To understand how these cells respond to miR-34a expression rescue, we artificially introduced miR-34a in these cells using miR-34a mimics. All of the cell lines showed decreased viability in the miR-34a-treated group compared with miR-Control, as measured by MTT assay ( Figure 1B ). Interestingly the IC50 values did not correlate with their basal miR-34a expression and the IC50 ranged from 5.60 to 40 nM, the highest of the tested doses ( Figure 1B ). We selected A549 cells for establishing a high-throughput screen based on observation that this cell line has low expression of miR-34a and is partially resistant to miR-34a rescue. This would provide a window to improve miR-34a therapy in combination with a small molecule. Furthermore, in A549 cells we tested the effect on expression of miR-34a downstream targets BCL2, CD44, JAG1, MET, MYC and observed that the majority of these downstream targets showed significant reductions in mRNA expression ( Figure 1C ). This further confirmed that A549 cells respond to miR-34a treatment and act as a suitable cell line for establishing a small molecule enhancer screen.
Establishing a Cell-Based System for miR-34a Enhancement
The doxycycline inducible expression system has been used widely in studies to control gene expression and perform investigations in a controlled manner. For the current study to screen small molecules acting synergistic with miR-34a, we established A549 cells with inducible overexpression of miR-34a. We cloned the miR-34a coding sequence into a lentiviral plasmid with TET response element adjacent to the promoter. Lentiviral particles were transduced into A549 cells, and we measured expression of miR-34a after addition of doxycycline ( Figure 2A ). Our data showed a dose-dependent increase in miR-34a expression at the 72-h time point ( Figure 2B ). We selected 1 mg/mL as a dose of doxycycline for subsequent experiments as this dose induced miR-34a level comparable with those found in the normal lung cell lines screened as per Figure 1A (for example, A549 cells showed $350-fold lower miR-34a compared with the average of SALE and AALE expression). We confirmed activity of induced miR-34a using a reporter plasmid containing miR-34a target sequence placed in the 3 0 UTR region of luciferase. Our data showed a significant decrease in luciferase signal upon induction with doxycycline at 1 mg/mL for 72 h ( Figure 2C ), confirming active miR-34a in A549 cells. Upon checking mRNA expression of miR-34a downstream targets, CD44 and SRC, our data showed a significant reduction at the 48-and 72-h time points, confirming that miR-34a is active in downstream signaling modulation ( Figure 2D ).
High-Throughput Assay Standardization for the Screen of Small Molecules to Combine Synergistically with miR-34a
For the phenotypic assay, we used detection of apoptosis induction (by measuring activated caspase 3) and the total number of cells (using Hoechst nuclear staining). Optimization of cell numbers and the HT assay was performed using A549-miR34 cells with a positive control compound, erlotinib, as previously we had seen combining miR-34a with erlotinib treatment showed a decrease in IC50 in vitro (Stahlhut and Slack, 2015) . An initial cell number screen showed that the optimal cell number in 384-well plates to show increased caspase activity and a significant decrease in cell numbers is 5,000 cells. Images showed a consistent increase in caspase 3 fluorescence signal in erlotinib treated or doxycycline combination groups (Figures S1A and S1B). Furthermore, the robustness of the established assay was measured using cells plated in 384-well plates in conditions similar to the small molecule screen conditions and signals were measured using an automated plate reader with robotic handling of plates. Data analysis for the Z factor showed a valid score of 0.91 for total cell count and 0.72 for caspase 3 + cells ( Figure 2E ). For all screening plates, the quality control Z factor was set to 0.5, and any plates below this threshold, were repeated.
Ouabain Sensitizes Lung Cancer Cells to miR-34a Treatment
Upon finalizing the phenotypic assay, cells with miR-34a induction were screened with 9,908 bioactive compounds (Table S1 , Figures S2A and S2B) for increased apoptosis and decreased cell numbers. XY plot of +dox versus Àdox readouts with all the molecules (n = 9,908) screened showed linearity and confirmed the robustness of the assay ( Figure 3A ). Furthermore, positive control erlotinib treatment points showed a shift toward the +dox axis in % caspase activity and shift toward Àdox axis with respect to total cell counts, verifying the validity of the assay and the data generated. Data from the small molecule screen for % decrease in cell numbers and caspase + cells was used for initial stratification of top candidates to be subsequently tested in a cherry pick screen (Figures 3B and Table S2 ). For the cherry pick screen, we included the top 48 molecules (two of fifty molecules were omitted as they belonged to the same family) from the initial screen and a six-point dose-response curve was plotted starting with the maximum feasible dose (IC50s and caspase 3-positive cells data are in Table S2 ). Our data showed similarity to the initial screen, and molecules repeated in terms of cell number decrease and increased caspase + cells upon miR-34a inductions. However, several of the 50 molecules did not reach an IC50 at the highest dose in control cells or miR-34a-induced cells; hence we used IC30 for selecting the next set of top candidates to move into combination index calculations with miR-34a transfections in multiple cell lines.
Based on our stringent criteria of decrease in IC30 (median 72% as cut off) and increased caspase-positive cells, we selected seven candidates from Table S3 for conducting Lowe's additivity combination index synergy analysis. Increasing doses of the top seven drugs in A549 and HCC827 cells, with increasing doses of miR-34a mimic transfection, were used. miR-Control was used to measure any cytotoxicity arising from transfection or drug class. Our data showed a maximum synergetic score and points in the matrix for ouabain followed by QNZ (Figures3C, S3A, and S2B). Furthermore, this synergy was not observed in miR-Control-treated combinations suggesting a role of miR-34a in causing synergistic decreases in viability as measured through total cell counts. We confirmed the observed synergy by using an MTT assay for viability in four lung cancer cell lines with varying mutational landscape A549, HCC827, H1975, and CALU6. Our data showed a significant shift in IC50 in all four cell lines and confirmed the role of ouabain in causing a synergistic decrease in viability with miR-34a treatment ( Figure 3D ).
Ouabain and miR-34a Combination Effects Are Seen in Pancreatic and Colon Cancer Cells and Patient-Derived Xenografts from Lung Cancer Patient
Considering that miR-34a is lost in many other cancers including pancreatic and colon cancers, we further explored the applicability of findings from this study to these cancers. We used the BXPC3 cell line for (E) Establishing the cell-based assay for detection of total cell counts and caspase 3-activated cells. DOX and Erlotinib were added to a set of A549-miR-34a cells plated in parallel, and total cell numbers and activated caspase 3-positive cell counts were taken, followed with data analysis to measure the Z-factor. pancreatic cancer and HCT116 and HCT15 cells for colon cancer. Our data with three different doses of ouabain showed a significant decrease in cell counts compared with control or individual ouabain, or miR-34a treatments ( Figure 4A ).
Patient-derived xenograft and primary 3-dimensional cell cultures (organoids) have been recently used in studies and are suggested to be closer to in vivo models than 2D cell cultures. In our current study we utilized such a system and established 3D patient-derived lung cancer spheroids embedded in low concentration of geltrex mixed in cell culture media. miR-Control-treated group showed normal growth of spheroids, and miR-34a or ouabain treatment resulted in a decreased number of spheroids ( Figure 4B ). However, the largest significant decrease was observed in miR-34a and ouabain-treated cells consistent with the monolayer cell culture findings above ( Figure 4B ).
Ouabain Acts Synergistically with miR-34a via Induction of Autophagy
During the course of study, we noticed that cells treated with ouabain showed a large number of vacuoles and this number increased in combination with miR-34a ( Figure 5A ). A comparison of our phase contrast images with those found in the literature indicated that the clear morphology changes we observed were consistent with autophagy (Parzych and Klionsky, 2014). To test this, cells were transduced with the Premo Autophagy Tandem Sensor RFP-GFP-LC3B system to study the definitive molecular changes related to autophagy. This sensor has an acid-sensitive GFP signal and acid-insensitive RFP signal upon induction of autophagy in cells. In the ouabain treatment group we observed increased autophagolysosome-(RFP) and autophagosome-(GFP) positive cells compared with control or miR-34a treatments ( Figure 5B ). Western blots of lysates from cells treated with miR-control, ouabain, miR-34a, and the combination showed increased LC3A/B signal and confirmed induction of autophagy ( Figure 5C ). All of these data suggested activation of autophagy and associated cell death when cells are treated with miR-34a and ouabain.
Conclusion
Of several hundred miRNAs identified in humans, a few have emerged as strong tumor suppressors, often lost owing to deregulation in the transcription machinery regulating particular miRNAs (Bartel, 2004; Rupaimoole and Slack, 2017) . One such miRNA is miR-34a, directly downstream of the p53 transcription factor (Chang et al., 2007) . Loss of p53 and related loss of expression of miR-34a has been reported in many cancers including lung cancer (Chang et al., 2007) . Reintroduction of tumor suppressor miRNAs has shown therapeutic efficacy against cancers, and miR-34a has progressed past preclinical studies into clinical trials (Kasinski and Slack, 2012; Trang et al., 2011) . In addition to delivery of miR-34a using nanoparticles, a preclinical study recently showed use of ligand-mediated in vivo delivery of miR-34a (Orellana et al., 2017) . MRX34, a clinical formulation of miR-34a in nanoliposomes had shown significant hepatic tumor reduction in in vivo xenograft studies (Beg et al., 2015) . Despite mostly manageable safety in the dose escalation phase of the early phases of the clinical trial, three patients developed immune-related serious adverse events and the trial was halted. This suggests that, despite the attractive promise of single agent miRNA therapy, there is a need for combination therapeutics, potentially decreasing the need for large single-dose compounds. In this study we screened $10,000 biologically active compounds for their potential to induce cell killing in combination with miR-34a in a synergistic manner. With multiple experimental validations, we identified ouabain as a small molecule capable of inducing significant cell killing even at low doses of ouabain and miR-34a. Previous studies have shown a role for ouabain and related cardiac glycosides in inducing cancer cell apoptosis mediated by direct inhibition of Na + K + ATPases (Cherniavsky-Lev et al., 2014) . Inhibition of ATPases resulted in induction of apoptosis via activation of JNK leading to decreased Bcl2 and releasing Beclin1, an autophagy inducer (Trenti et al., 2014) . In parallel to this study, our data suggest that, upon combination with miR-34a, LC3 production and cleavage, definitive markers of autophagy were increased. Furthermore, these data directly correlate with decreased cell viability and increased apoptosis measured via Caspase 3 signals. In the end, our data provide evidence for use of ouabain as a combination therapeutic with miR-34a against lung cancer and similar cancers with loss of miR-34a. These data will serve as a strong basis for future preclinical trials involving miR-34a treatment in lung cancer.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file. Trang, P., Wiggins, J.F., Daige, C.L., Cho, C., Omotola, M., Brown, D., Weidhaas, J.B., Bader, A.G., and Slack, F.J. (2011) . Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther. 19, 1116 -1122 . Trenti, A., Grumati, P., Cusinato, F., Orso, G., Bonaldo, P., and Trevisi, L. (2014 . Cardiac glycoside ouabain induces autophagic cell death in non-small cell lung cancer cells via a JNK-dependent decrease of Bcl-2. Biochem. Pharmacol. 89, 197-209. Zhang, W.C., Wells, J.M., Chow, K.-H., Huang, H., Yuan, M., Saxena, T., Melnick, M.A., Politi, K., Asara, J.M., Costa, D.B., et al. (2019) . miR-147bmediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma. Nat. Metab. 1, [460] [461] [462] [463] [464] [465] [466] [467] [468] [469] [470] [471] [472] [473] [474] iScience, Volume 23 This library contains 1120 off-patent compounds that have been selected for structural diversity, collective coverage of multiple therapeutic areas, and known safety and bioavailability in humans Cayman Biolipid
Supplemental Information
Included are prostaglandins, thromboxanes, cannabinoids, D-myo-inositol-phosphates, phosphatidylinositol-phosphates, sphingolipids, inhibitors, receptor agonists and antagonists, ceramide derivatives, and several other complex polyunsaturated fatty acids Biomol ICCB known bioactives
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Transparent Methods
Cell line maintenance, microRNA mimic transfections, and establishing cell lines for screen
All cell lines used in the study were maintained in 5% CO2, 37 0 C standard cell culture incubators, with weekly media change and close monitoring. All the cell lines used in the study were obtained from American type cell culture collection (ATCC) and maintained in RPMI1640 medium supplemented with 15% FBS and antibiotics. All cell lines were routinely tested for mycoplasma. Lung cancer patient derived xenograft (PDX) was obtained and processed as previously discussed (Zhang et al., 2019) et al., 2019) . For each 96 wells containing spheroids, 10^3 cells were plated in the above mixture of Matrigel and media, incubated for 7 days before transfection with miRNA control and miR-34a as per below protocol.
For miRNA transfections, RNAiMAX Lipofectamine (Life Technologies) was used as a transfection agent, and the ratio of RNAiMAX to a specific miRNA was 2:1 (nM to ul). The concentration of miRNAs used for transfection was set to 40nM. Briefly, miRNA mimics for miR-34a and control miRNA (Life Technologies) were diluted in Opti-MEM media and liposomal complex was prepared by adding RNAiMAX reagent. The mixture was incubated for 15 min before adding to the cell mixture in complete media and incubated for the specific time frame of the studies mentioned below.
For the small molecule screen, A549 and HCC827 cells were transduced with lentiviral particles containing miR-34a
overexpression system under tight control of a tetracycline responsive element (TET, doxycycline inducible). Using constitutive eGFP, cells were selected in two rounds for actively transduced cells. For inducing miR-34a expression, doxycycline (Sigma Aldrich) was added at different doses in 6 well plate cultures of A549 and HCC827 cells previously transduced with lentiviral particles containing miR-34a over expression plasmid. Using qPCR, induction of miR-34a expression and downstream target CD44 (Liu et al., 2011) and SRC (Adams et al., 2016) mRNA changes were measured.
High-throughput screen (HTS) to identify miR-34a synergistic small compounds HTS was standardized and performed against 9908 small molecule compounds which are part of biologically active small molecule collection at the ICCB Longwood screening facility (Harvard Medical School). In 384 well plates, assays to count the total number of cells and activated caspase using Nucview 549 probe (Biotium) were standardized.
As a positive control, Erlotinib at IC50 dose for A549 cells was used in every screening plate (two replicates per compound). Post plating A549-miR-34a cells with 1 ug/ml of doxycycline, compounds were transferred to individual wells using a pin-transfer system, and the plates were incubated at 37°C in 5% CO2 for 72 hr. After the incubation period, cell plates were removed, washed with PBS and incubated with Hoechst 33342 (Thermofisher) and Nucview 549 (Biotium) for 10min and cells were fixed with 4% paraformaldehyde. Signals from each well were quantified using Acumen eX3 high content imager (TTPLabtech) and data plotted as % total cells and % caspase positive cells compared to control DMSO treatments. The Z-factor was used for quality control purposes and each plate's positive control and negative control readings were used for calculations. A Z-factor of 0.5 was used as cutoff for quality control of each plate and assay. The top 10% of compounds with the highest decrease in viability and further cutoff of an increase in caspase 3+ cells (n=58) were used for a cherry pick screen with a dose response curve. Further combination index analysis on the top selected candidates were performed with miR-34a or miR-control at increasing doses in a matrix of increasing dose of compounds. Data analysis using Combenefit (Di Veroli et al., 2016) tool with Loews additivity combination calculations were carried out. The top two compound with significant synergy points were used for further analysis. Raw data from the screen deposited at Pubchem with AID 1347080.
Immunoblotting and Quantitative real-time PCR
For Western blotting, lysates from cultured cells were prepared using modified RIPA buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton, 0.5% deoxycholate) plus Halt phosphatase and protease inhibitor cocktail (Pierce Biotechnology) at 1x concentration. The protein concentrations were determined using a BCA Protein Assay Reagent kit (Pierce Biotechnology). Lysates were loaded and separated on SDS-PAGE. Proteins were transferred to a nitrocellulose membrane by semidry electrophoresis (Bio-Rad Laboratories) overnight, blocked with 5% BSA for 1 h and then incubated at 4 °C overnight with primary antibody against LC3A/B 1:500 (Novus Biologicals). After washing with TRIS-buffered saline with Tween 20, the membrane was incubated with horseradish peroxidase-conjugated horse anti-Mouse or Rabbit IgG (1:2,000, GE Healthcare) for 2 h. Horseradish peroxidase was visualized using an enhanced chemiluminescence detection kit (Pierce Biotechnology). To confirm equal sample loading, the blots were probed with an antibody specific for β-actin (0.1 µg ml −1 ; Sigma).
For mRNA and miRNA quantification, total RNA was isolated using the Direct-zol™ RNA MiniPrep Plus kit following the manufacturer protocol (Zymo Research). For mRNA measurements, 1,000 ng of RNA was used to synthesize complementary DNA using a Verso cDNA kit (Thermo Scientific), as per the manufacturer's instructions.
Analysis of mRNA levels was performed on a Roche 384 Real-Time PCR System (Roche) using pre-validated (Qiagen) primers specific for each of the genes. Semi-quantitative real-time PCR was done with reverse-transcribed RNA and 100 ng µl −1 sense and antisense primers in a total volume of 10 µl. For miRNA quantification TaqMan miRNA assays (Life Technologies) were used and reverse transcription, real-time PCR were carried out, according to the manufacturer's instructions. RNU6B (for mature miRNAs) or 18S (mRNAs) were used as a housekeeping gene.
Detection of autophagy in miR-34a and ouabain treated cells
Measurement of autophagy in cells treated with control miRNA and miR-34a with or without ouabain was carried out using the Premo™ Autophagy Tandem Sensor RFP-GFP-LC3B Kit (Thermo Fisher Scientific) as described in the manufacturer's instructions. The RFP-GFP-LC3B sensor enables the detection of LC3B positive, neutral pH autophagosomes in green fluorescence (GFP) and LC3B positive acidic pH autophagolysosome in red fluorescence (RFP). The cells were grown on chamber slides with transfection of miR-34a or miR-control. Following transfections, cells were treated with ouabain (30nM) or DMSO control and incubated with BacMam Reagents containing the RFP-GFP-LC3B overnight. Treatment was done for total of 24hrs and cells were washed with PBS, nuclei were stained with Hoechst 33342. Fluorescent images were taken using confocal microscopy (Carl Zeiss Meditec). LC3B positive autophagosomes (green) and LC3B positive autophagolysosome (red) were analyzed as ratio of percentage of RFP and GFP positive cells compared total cells per field (200x).
Statistics
For all the data presented, graphs were plotted using Prism (Graphpad Software). For all statistical comparisons, Student's t test or ANOVA were used with multiple comparison tests. P value for significance was set at minimum of 0.05. Data is representative of triplicate experiments, unless otherwise mentioned in figure legends.
